Replies to post #7149 on Biotech Values

[DewDiligence]

>>SRDX's vitreal implant could make stent royalties look like small potatoes…<<

Double-digit royalties would sure beat the 1% rate on Cypher.

By the way, my question on the SRDX board for the annual meeting was only half in jest. Given that the former COO is known to read the board and we talk about AMD all the time, is it such a stretch? Regards, Dew